Cullinan Therapeutics (CGEM) Current Assets (2020 - 2026)

Cullinan Therapeutics' Current Assets history runs 7 years deep, the most recent figure standing at $361.4 million for Q1 2026.

• In Q1 2026, Current Assets rose 13.73% year-over-year to $361.4 million; the TTM figure through Mar 2026 stood at $361.4 million (up 13.73% YoY), while the FY2025 annual figure was $386.8 million, down 6.73% from the prior year.
• Current Assets for Q1 2026 stood at $361.4 million, down from $386.8 million in the prior quarter.
• The five-year high for Current Assets was $677.8 million in Q2 2024, with the low at $275.9 million in Q2 2025.
• The 5-year median for Current Assets is $445.7 million (2024), against an average of $451.2 million.
• The sharpest annual moves came in 2022 and 2025: Current Assets surged 80.81% in 2022, then slumped 59.29% in 2025.
• Cullinan Therapeutics' Current Assets stood at $474.5 million in 2022, then advanced by 1.21% to $480.2 million in 2023, then declined by 13.65% to $414.7 million in 2024, then decreased by 6.73% to $386.8 million in 2025, then decreased by 6.55% to $361.4 million in 2026.
• Business Quant data shows CGEM's Current Assets at $361.4 million in Q1 2026, $386.8 million in Q4 2025, and $342.2 million in Q3 2025.